Business
Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
Report focuses on patient access and affordability, workforce wellness and training, community involvement and sound corporate governance WALTHAM, Mass., Feb.
About this update from Ardelyx, Inc.
[{"type":"text","content":"Report focuses on patient access and affordability, workforce wellness and training, community involvement and sound corporate governance\nWALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today published its 2022 Environmental, Social and Governance (ESG) Report, the first time the company has reported on its sustainability efforts in these areas. “I am pleased to share our 2022 Ardelyx ESG report, which showcases the ways we have invested in our patients, employees and the communities we serve, to build a more equitable and sustainable society,” said Mike Raab, president and chief executive officer of Ardelyx. “In recent years, we have proven our resilience as a company, as a society and as individuals, and all of us at Ardelyx are committed to continuing to adapt and grow. While we are still early in our ESG journey, I am proud of the foundation and culture within Ardelyx that embraces social consciousness and sustainability. We look forward to continuing to work with our stakeholders, with a priority towards the patients we seek to serve, to shape a better future for all.” Highlights from Ardelyx’s ESG activities in 2022 include: Created ArdelyxAssist™, a patient services program designed to provide a broad range of access and affordability support for patients and health care providersDonated more than $2 million to support educational programs for healthcare providers, patients and caregiversDonated more than eleven pallets and six truckloads of R&D supplies and equipment to non-profit STEM organizationsSponsored the California Life Sciences Association Racial and Social Equity Initiative, a first step in a unified effort for the life sciences industry in California to do more for the under-served and under-representedNamed one of the “Deloitte Technology Fast 500™,” a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America The ESG report details areas of the company’s ESG focus, including patient access and affordability; product quality management and safety; clinical study standards; patient advocacy and corporate giving; training and develo...